ESC 365 - PCSK9 inhibitors: from pre-clinical research to clinical practice.

Open Access

PCSK9 inhibitors: from pre-clinical research to clinical practice.

Session: PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

Topic: Prevention

Speaker: Doctor C. Ballantyne (Houston, US)

Sponsored by Amgen (Europe) GmbH

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)

29 presentations

3 followers

4 more presentations in this session

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients. - Sponsored by Amgen (Europe) GmbH.

Managing patients with PCSK9 inhibitors: navigating the continuum of cardiovascular risk.

Speaker: Professor G. De Ferrari (Turin, IT)

PCSK9 inhibitors: what can we learn from 5 years of real-world use? EU data.

Speaker: Professor K. Ray (London, GB)

PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.

Speaker: Professor S. Goodman (Toronto, CA)

Access the full session

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

Speakers: Doctor C. Ballantyne, Professor G. De Ferrari, Professor K. Ray, Professor S. Goodman

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources